We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+7.77%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$800M
AUM Growth
+$24M
Cap. Flow
+$23.2M
Cap. Flow %
2.9%
Top 10 Hldgs %
39.52%
Holding
76
New
14
Increased
22
Reduced
26
Closed
9

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$25.8M
2
ABT icon
Abbott
ABT
+$21.2M
3
LLY icon
Eli Lilly
LLY
+$14M
4
CELG
Celgene Corp
CELG
+$11.6M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.89M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19M
2
MRK icon
Merck
MRK
+$12.6M
3
MOH icon
Molina Healthcare
MOH
+$12.1M
4
TSRO
TESARO, Inc.
TSRO
+$11.1M
5
ABMD
Abiomed Inc
ABMD
+$8.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
51
DELISTED
TESARO, Inc.
TSRO
$3.03M 0.38%
36,600
-113,199
-76% -$11.1M
SAGE
52
DELISTED
Sage Therapeutics
SAGE
$2.83M 0.35%
+17,200
New +$1.67M
INSM icon
53
Insmed
INSM
$23.2B
$2.81M 0.35%
90,199
+27,800
+45% +$821K
AGIO icon
54
Agios Pharmaceuticals
AGIO
$2.16B
$2.73M 0.34%
47,799
– –
ARAY icon
55
Accuray
ARAY
$28.4M
$2.56M 0.32%
595,447
-92,100
-13% -$423K
SVRA icon
56
Savara
SVRA
$1.13B
$2.37M 0.3%
+160,000
New +$1.84M
OBSV
57
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.06M 0.26%
211,407
-1,424
-0.7% -$14.5K
INDP icon
58
Indaptus Therapeutics
INDP
$348M
$1.83M 0.23%
158
– –
KA
59
DELISTED
Kineta, Inc. Common Stock
KA
$1.75M 0.22%
+2,143
New +$822K
FSTX
60
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$1.66M 0.21%
30,846
– –
ESPR
61
DELISTED
Esperion Therapeutics
ESPR
$1.54M 0.19%
+23,333
New +$1.26M
PBYI icon
62
Puma Biotechnology
PBYI
$406M
$1.49M 0.19%
+15,050
New +$1.68M
DBVT
63
DBV Technologies
DBVT
$807M
$1.48M 0.19%
6,030
+750
+14% +$217K
CMTA
64
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$1.43M 0.18%
75,313
+45,000
+148% +$753K
ZLAB icon
65
Zai Lab
ZLAB
$2.17B
$1.05M 0.13%
49,584
-216,016
-81% -$5.75M
RDY icon
66
Dr. Reddy's Laboratories
RDY
$9.82B
$958K 0.12%
127,480
-101,500
-44% -$731K
SRRA
67
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$752K 0.09%
5,042
– –
GILD icon
68
Gilead Sciences
GILD
$161B
– –
-234,900
Closed -$19M
ILMN icon
69
Illumina
ILMN
$29.4B
– –
-9,612
Closed -$1.86M
TGTX icon
70
TG Therapeutics
TGTX
$8.58B
– –
-100,366
Closed -$1.19M
NUVA
71
DELISTED
NuVasive, Inc.
NUVA
– –
-132,290
Closed -$7.34M
TRIL
72
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-234,248
Closed -$1.21M
RARX
73
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-278,082
Closed -$4.06M
NXTM
74
DELISTED
NxStage Medical Inc.
NXTM
– –
-98,579
Closed -$2.72M
EVHC
75
DELISTED
Envision Healthcare Holdings Inc
EVHC
– –
-113,600
Closed -$5.11M
1 2
3
4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sectoral Asset Management held 76 positions worth $800M, up 3.1% from $776M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Sectoral Asset Management's Q4 2017 filing shows 14 new, 22 increased, 26 reduced and 9 closed positions. Its largest new stake was Apellis Pharmaceuticals: 1,752,655 shares worth $38M. The largest sale was Gilead Sciences, an estimated $19M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

  • Sectoral Asset Management's largest Q4 2017 buy was Apellis Pharmaceuticals: 1,752,655 shares worth $38M.
  • Sectoral Asset Management added most to Celgene Corp in Q4 2017, an estimated $11.6M increase.
  • Sectoral Asset Management's biggest Q4 2017 reduction was Merck, cutting an estimated $12.6M.
  • Sectoral Asset Management fully exited Gilead Sciences in Q4 2017, selling an estimated $19M.
  • Sectoral Asset Management's ten largest holdings make up 40% of its $800M portfolio in Q4 2017.
  • Sectoral Asset Management opened 14 new positions and closed 9 in Q4 2017.
  • Sectoral Asset Management's portfolio value rose 3.1% quarter-over-quarter to $800M.

Based on Sectoral Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.